Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study
Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study
复制标题
DOI：
10.1136/bmjopen-2018-027193
复制
发表时间：
2019-08
期刊：
影响因子：
2.9
通讯作者：
Yangyang Cheng;Chi-Kwong Tung;A. K. Chung;Wan-Wan Liu-Wan;Duo Huang;Pak-hei Chan;M. Lam;W. Chan;C. Siu;J. Hai
中科院分区：
文献类型：
--
作者：
Yangyang Cheng;Chi-Kwong Tung;A. K. Chung;Wan-Wan Liu-Wan;Duo Huang;Pak-hei Chan;M. Lam;W. Chan;C. Siu;J. Hai
甲基苯丙胺滥用被归类为肺动脉高压（PAH）的“可能”风险因素。然而，甲基苯丙胺使用者中PAH的实际患病率和筛查策略尚未确定。我们计划研究PAH的患病率，并确定其在甲基苯丙胺使用者中的独立危险因素。方法和分析甲基苯丙胺滥用者肺动脉高压筛查（SOPHMA）研究将是一项多中心、横断面筛查研究，将涉及香港的药物滥用诊所、医院和康复机构，为20多名甲基苯丙胺使用者提供服务。将纳入共计400例患者，这些患者（1）入组时年龄≥18岁;（2）在过去2年内报告使用甲基苯丙胺;（3）诊断为甲基苯丙胺使用障碍;（4）通过提供书面知情同意书自愿同意参与研究。患者将接受推荐用于系统性硬化症患者的标准超声心动图PAH筛查程序。将为具有中度或高度PAH超声心动图可能性的受试者提供右心导管插入术。对于超声心动图显示PAH概率较低的受试者，将在1年内进行重新筛选。主要措施将是甲基苯丙胺使用者中PAH的流行率。次要措施将是甲基苯丙胺使用者PAH的风险因素和预测模型。SOPHMA研究已获得机构审查委员会的批准。这项研究的结果将提供必要的证据，建立普遍的指导方针，筛查PAH的甲基苯丙胺用户。我们的研究结果将通过向研究参与者提供即时反馈、向公众发布新闻稿以及在医学会议上发表和在同行评审期刊上向全球医疗保健提供者和学术界发表的方式传播。
Introduction Methamphetamine misuse is classified as a ‘likely’ risk factor for pulmonary arterial hypertension (PAH). Nevertheless, the actual prevalence of and a screening strategy for PAH in methamphetamine users have not been established. We plan to study the prevalence of PAH and identify its independent risk factors among methamphetamine users. Methods and analysis The Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA) study will be a multicentre, cross-sectional screening study that will involve substance abuse clinics, hospitals and rehabilitation facilities in Hong Kong that cater to more than 20 methamphetamine users. A total of 400 patients who (1) are ≥18 years at enrolment; (2) report methamphetamine use in the last 2 years; (3) are diagnosed with methamphetamine use disorder; and (4) voluntarily agree to participate by providing written informed consent will be included. Patients will undergo standard echocardiography-based PAH screening procedures recommended for those with systemic sclerosis. Right heart catheterisation will be offered to participants with intermediate or high echocardiographic probability of PAH. For participants with a low echocardiographic probability of PAH, rescreening will be performed within 1 year. The primary measure will be the prevalence of PAH in methamphetamine users. The secondary measures will be the risk factors and a prediction model for PAH in methamphetamine users. Ethics and dissemination The SOPHMA study has been approved by the institutional review board. The findings of this study will provide the necessary evidence to establish universal guidelines for screening of PAH in methamphetamine users. Our results will be disseminated through immediate feedback to study participants, press release to the general public, as well as presentation in medical conferences and publications in peer-reviewed journals to healthcare providers and academia worldwide.